AAP
BCAX

Arax Advisory Partners’s Bicara Therapeutics BCAX Stock Holding History

Arax Advisory Partners’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$159 Buy
8
+5
+167% +$86 ﹤0.01% 3569
2025
Q4 		$50 Sell
3
-67
-96% -$1.14K ﹤0.01% 3917
2025
Q3 		$1.1K Buy
70
+11
+19% +$123 ﹤0.01% 3237
2025
Q2 		$549 Buy
+59
New +$703 ﹤0.01% 2923

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Arax Advisory Partners's BCAX Position: Q1 2026 in Review

Arax Advisory Partners increased its Bicara Therapeutics (BCAX) stake by 167% in Q1 2026, buying an estimated $86 and bringing the position to 8 shares worth $159. The position accounts for ﹤0.01% of the portfolio, ranked #3569.

Arax Advisory Partners first reported a position in BCAX in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.1K in Q3 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Arax Advisory Partners held 8 shares of Bicara Therapeutics worth $159 as of Q1 2026.
  • Arax Advisory Partners bought 5 Bicara Therapeutics shares in Q1 2026, an estimated $86.
  • Bicara Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3569 holding.
  • Arax Advisory Partners first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's Bicara Therapeutics position peaked at $1.1K in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.